This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
Wes Yin, PhD
Advertisement
Articles by Wes Yin, PhD
This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.
Advertisement
Latest Updated Articles
- The Value of Survival Gains in Myelodysplastic Syndromes
Published: January 16th 2017 | Updated:
- The Relationship Between Adherence and Total Spending Among Medicare Beneficiaries With Type 2 Diabetes
Published: April 19th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
5
